Balaji Prasad
Stock Analyst at Barclays
(2.77)
# 1,937
Out of 5,147 analysts
147
Total ratings
48.78%
Success rate
4.54%
Average return
Main Sectors:
Stocks Rated by Balaji Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Overweight | $22 → $25 | $4.30 | +481.40% | 8 | Mar 5, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $10 → $11 | $13.81 | -20.35% | 5 | Mar 3, 2025 | |
| PCRX Pacira BioSciences | Maintains: Overweight | $17 → $24 | $21.91 | +9.54% | 9 | Feb 28, 2025 | |
| VTRS Viatris | Maintains: Underweight | $12 → $9 | $14.93 | -39.72% | 8 | Feb 28, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $190 → $200 | $190.02 | +5.25% | 10 | Feb 27, 2025 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $20 → $19 | $26.40 | -28.03% | 13 | Feb 26, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Overweight | $62 → $60 | $75.52 | -20.55% | 5 | Feb 26, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $242 → $244 | $131.10 | +86.12% | 16 | Feb 14, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $26 → $24 | $7.29 | +229.22% | 2 | Feb 14, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underweight | $20 → $22 | $54.59 | -59.70% | 8 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $481 → $520 | $656.73 | -20.82% | 9 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $33.86 | -23.21% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $150 → $160 | $198.31 | -19.32% | 15 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $17 | $14.38 | +18.22% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $18 | $3.99 | +351.13% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $10 | $4.25 | +135.29% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $1.67 | +319.16% | 7 | Oct 23, 2023 |
Evolus
Mar 5, 2025
Maintains: Overweight
Price Target: $22 → $25
Current: $4.30
Upside: +481.40%
Amneal Pharmaceuticals
Mar 3, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $13.81
Upside: -20.35%
Pacira BioSciences
Feb 28, 2025
Maintains: Overweight
Price Target: $17 → $24
Current: $21.91
Upside: +9.54%
Viatris
Feb 28, 2025
Maintains: Underweight
Price Target: $12 → $9
Current: $14.93
Upside: -39.72%
Jazz Pharmaceuticals
Feb 27, 2025
Maintains: Overweight
Price Target: $190 → $200
Current: $190.02
Upside: +5.25%
Elanco Animal Health
Feb 26, 2025
Maintains: Overweight
Price Target: $20 → $19
Current: $26.40
Upside: -28.03%
Tarsus Pharmaceuticals
Feb 26, 2025
Maintains: Overweight
Price Target: $62 → $60
Current: $75.52
Upside: -20.55%
Zoetis
Feb 14, 2025
Maintains: Overweight
Price Target: $242 → $244
Current: $131.10
Upside: +86.12%
Organon & Co.
Feb 14, 2025
Maintains: Overweight
Price Target: $26 → $24
Current: $7.29
Upside: +229.22%
Phibro Animal Health
Feb 10, 2025
Maintains: Underweight
Price Target: $20 → $22
Current: $54.59
Upside: -59.70%
Feb 4, 2025
Maintains: Overweight
Price Target: $481 → $520
Current: $656.73
Upside: -20.82%
Jan 30, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $33.86
Upside: -23.21%
Dec 16, 2024
Maintains: Overweight
Price Target: $150 → $160
Current: $198.31
Upside: -19.32%
Nov 6, 2024
Maintains: Overweight
Price Target: $17 → $17
Current: $14.38
Upside: +18.22%
Jul 25, 2024
Maintains: Overweight
Price Target: $22 → $18
Current: $3.99
Upside: +351.13%
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $4.25
Upside: +135.29%
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $1.67
Upside: +319.16%